Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Halozyme Therapeutics, Inc. HALO

Healthcare — Biotechnology
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
41.20
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 3 2 1 1 2 2 2 3 2 2 2
Insider Ownership
4.28%

Capital & Financial Ratios

Market Cap
12,260.00
Revenue
1,663.74
Net Income
413.60
Free Cash Flow
806.22
Net Debt
1,915.65
Current Ratio
2.71
Debt/Equity
14.95
P/E ratio
31.95
P/S ratio
7.93
P/B ratio
91.87
Past 5Y EPS Growth
26.15%
This Y EPS Growth
102.75%
Next Y EPS Growth
22.39%
Next 5Y EPS Growth
41.35%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 336.00 596.07 142.82 231.00
Receivables 234.21 308.46 441.27 455.83
Inventory 127.60 141.86 176.48 137.14
Other — — — —
746.42 1,085.34 825.21 933.02
2023 2024 2025 Q'26
Payables 11.82 10.25 20.90 23.61
ST’ Debt — — — 208.97
Other — — — —
112.49 139.10 177.09 344.44
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 376.71 481.00 — —
—
’25 264.86 325.72 354.26 451.77
1,396.61
’24 195.88 231.35 290.08 298.01
1,015.32
’23 162.14 221.04 216.03 230.04
829.25
’22 117.28 152.37 208.98 181.50
660.12
’21 89.02 136.46 115.83 102.00
443.31
’20 25.35 55.22 65.32 121.70
267.59
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 180.08 240.89 — —
—
’25 154.22 99.71 178.60 219.03
651.56
’24 129.43 55.79 115.38 178.47
479.06
’23 86.96 66.84 132.41 102.35
388.57
’22 47.80 40.23 69.64 82.45
240.11
’21 58.30 36.89 121.74 82.52
299.44
’20 (4.84) 3.29 6.08 50.92
55.45
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 176.34 236.72 — —
—
’25 153.27 98.15 624.44 (231.27)
644.59
’24 125.88 53.21 425.46 (136.18)
468.37
’23 75.59 68.47 325.16 (95.94)
373.28
’22 47.31 55.28 68.63 90.09
261.31
’21 58.03 36.36 121.24 82.36
297.98
’20 (4.22) 2.78 6.03 49.44
54.03
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.22 1.90 — —
—
’25 0.93 1.33 1.43 (1.20)
2.56
’24 0.60 0.72 1.05 1.06
3.43
’23 0.29 0.56 0.61 0.65
2.10
’22 0.43 0.16 0.44 0.42
1.44
’21 0.19 0.62 1.48 0.46
2.74
’20 (0.04) 0.19 0.25 0.50
0.91

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.7
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 31.36 29.85 33.15 47.50 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 59.46 57.00 65.53 79.50 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 393 373 350 423 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.68 2.22 2.90 3.30 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 660.12 829.25 1,015.32 1,396.61 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 78.90% 76.80% 84.30% 83.62% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 248.92 348.33 557.13 466.88 ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.71% 42.01% 54.87% 33.43% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 202.13 281.59 444.09 316.89 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 58.59 85.84 77.74 92.26 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.82 6.29 8.01 11.65 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 1.48 2.13 3.50 2.64 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.75 2.95 3.78 5.44 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.15 (0.12) (0.08) (0.06) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.91 2.83 3.69 5.38 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.24 0.64 2.87 0.41 ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 136.84 131.93 126.83 119.84 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 37.25 17.47 13.66 25.79 ‡‡‡‡ ‡‡‡‡ ‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.43 5.95 5.97 5.77 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 44.43 58.86 16.67 165.22 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.16 7.39 6.90 7.72 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 33.25 16.42 14.96 16.72 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 240.11 388.57 479.06 651.56 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 21.20 (15.29) (10.70) (6.97) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 261.31 373.28 468.37 644.59 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 608.22 633.93 946.24 648.12 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,506.10 1,499.25 1,505.80 2,142.63 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,143.31 1,163.25 909.72 1,999.81 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 169.80 83.81 363.82 48.81 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 13.72% 15.75% 23.39% 13.81% ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.73% 16.92% 27.06% 14.31% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 110.23% 222.07% 198.42% 153.59% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Halozyme Therapeutics (HALO) is revolutionizing biotech with its ENHANZE platform, enabling subcutaneous delivery of biologics and powering lucrative royalties from partners like Roche, Pfizer, and Janssen. Revenue has exploded from $147 million in 2016 to $1.02 billion in 2024—a 592% surge at over 30% CAGR—driven by efficiency gains like revenue per employee tripling to $2.9 million. Analysts forecast continued acceleration to $1.39 billion in 2025 (37% YoY) and nearly $2 billion by 2027, fueled by oncology and immunology demand, FDA approvals, and new deals.

Profitability has transformed HALO from mid-2010s losses into a cash machine, with net income hitting $444 million in 2024 (EBT margins at 54.9%) and EPS soaring from -$0.81 to $3.50, projected to $8.90 by 2027. Free cash flow jumped 1,058% to support buybacks and growth, while a resilient balance sheet covers debt 2x over. Trading at a discounted 13.7x trailing P/E (forward 10.7x by 2026), HALO looks undervalued versus peers, with stock gains historically tracking earnings beats.

Routine insider selling amid highs signals confidence, not concern, as catalysts like ENHANZE expansions, partnership ramps, and 25%+ CAGR loom. Wall Street sees upside potential, but the bull case points to 50%+ returns over 2-3 years in this patient-friendly injectable shift—read the full analysis for the powder keg details.

Read full commentary →

Halozyme Therapeutics, Inc. (HALO) Latest News

News by impact score

Fine-tune

17 Sep

3 , 11:20 PM
Halozyme Therapeutics priced an upsized private offering of $1.3 billion in convertible senior notes due 2033. The $1.3 billion convertible notes raise substantial capital that supports operations but creates dilution risk without altering core business trajectory.

16 Sep

3 , 4:30 PM
Halozyme Therapeutics proposes offering $1.05 billion of convertible senior notes due 2033. Large convertible note issuance supplies substantial capital while introducing potential future share dilution.

3 , 12:45 PM
Halozyme Therapeutics (HALO) presents three reasons why growth investors should consider the stock, highlighting its strong growth prospects and market positioning. Positive growth analysis may lift investor sentiment and support near-term stock performance without major operational shifts.

21 Aug

3 , 12:23 PM
Halozyme Therapeutics (HALO) shares rose 36% over the past month on positive company developments. Recent stock gains signal improved sentiment but do not indicate fundamental shifts in operations or long-term trajectory.

15 Aug

3 , 2:05 AM
Halozyme Therapeutics Q2 earnings call drew analyst questions on revenue trends, ENHANZE platform growth, product pipeline updates, partnership deals, and 2024 financial guidance. Q2 earnings call questions reflect investor focus on near-term results and pipeline progress without signaling major strategic shifts.

13 Aug

3 transcript www.fool.com, 6:28 PM
Halozyme (HALO) Q2 2026 earnings call transcript details financial results, revenue figures, operational updates, and executive outlook on future performance. Quarterly earnings calls deliver financial metrics and guidance that moderately shape near-term investor sentiment and stock movement.

11 Aug

4 , 5:33 AM
Halozyme Therapeutics diversified royalty streams and advanced its pipeline in Q2, prompting upgraded company guidance. Royalty diversification and pipeline progress drove upgraded guidance, signaling major positive shifts in Halozyme's trajectory.

3 , 12:29 AM
Halozyme Therapeutics (HALO) shares have surged sharply higher. Sharp share price increase can lift near-term investor sentiment and visibility.

8 Aug

4 , 8:19 PM
Halozyme Therapeutics raised its 2026 revenue outlook and boosted share buybacks, driving a 24.9% stock surge. Revenue outlook raise combined with larger buybacks signals stronger growth and directly lifts shareholder value.

4 , 12:12 PM
Halozyme Therapeutics beat earnings expectations and raised guidance, raising questions over whether the stock is fairly valued at current levels. Earnings beat combined with raised guidance signals stronger financial momentum that can materially shift investor sentiment and valuation trajectory.

7 Aug

4 transcript , 11:06 PM
Halozyme Therapeutics reported record revenue and royalty income during its Q2 2026 earnings call. Record revenue and royalties demonstrate strong financial results that can drive major shifts in stock valuation and market perception.

4 transcript app.moby.co, 8:30 AM
Halozyme Therapeutics reported Q2 2026 earnings and provided operational updates during its earnings call. Earnings results and forward guidance directly shape investor views and near-term stock movement.

6 Aug

4 , 4:45 PM
Halozyme Therapeutics beat Q2 CY2026 expectations and guided for strong full-year sales. Earnings beat combined with positive full-year guidance signals stronger revenue trajectory and investor sentiment.

4 , 4:01 PM
Halozyme Therapeutics reported record second quarter 2026 results that beat estimates and raised its full year 2026 financial guidance. Record quarterly results combined with raised annual guidance indicate strong performance that can significantly lift investor sentiment and company trajectory.

3 transcript www.marketbeat.com, 10:03 PM
Halozyme Therapeutics Q2 earnings call highlights financial results and outlook. Quarterly earnings calls often shift near-term stock sentiment and valuations.

21 Jul

4 , 11:10 AM
Halozyme Therapeutics signed a new Enhanze collaboration deal with Incyte in precision oncology, expanding royalty revenue potential from drug delivery technology. New Incyte Enhanze deal expands Halozyme royalty engine in precision oncology and alters long-term revenue trajectory.

4 , 10:38 AM
Halozyme Therapeutics has signed a deal with Incyte to support cancer therapy development. Deal with INCY to support cancer therapy development signals major strategic advancement for HALO.

4 www.hospitalmanagement.net, 5:31 AM
Halozyme Therapeutics has signed a license agreement with Incyte for INCA033989 formulations. New licensing deal with Incyte directly expands Halozyme revenue potential via its core formulation technology.

3 www.pharmaceutical-technology.com, 5:31 AM
Halozyme Therapeutics signed a license agreement with Incyte covering formulations of INCA033989. Licensing deal with Incyte expands Halozyme partnership portfolio and creates additional royalty potential.

20 Jul

4 investorshub.advfn.com, 11:02 AM
Halozyme signs ENHANZE collaboration with Incyte to enable subcutaneous development of INCA033989. New ENHANZE licensing deal with Incyte expands platform revenue potential and pipeline reach.

4 , 8:00 AM
Halozyme enters global collaboration and license agreement with Incyte to develop subcutaneous formulations of INCA033989 using ENHANZE technology. Partnership expands ENHANZE applications and adds new licensing revenue for Halozyme.

15 Jul

4 , 9:46 AM
Halozyme Therapeutics (HALO) is positioned as an undervalued stock with ongoing successes in cancer treatment. Ongoing wins in cancer treatment signal major strategic progress likely to shift company trajectory and investor sentiment.

4 Jun

3 Simply Wall St., 9:15 AM
New ENHANZE data and analyst support have shifted the investment outlook for Halozyme Therapeutics (HALO). New ENHANZE data plus analyst support will moderately affect Halozyme financial performance and positioning.

3 Jun

3 , 8:15 PM
Halozyme Therapeutics (HALO) stock rises sharply today on positive developments driving investor buying. Stock surge signals moderate short-term market reaction without evidence of fundamental long-term shift.

19 May

3 StockStory, 7:40 PM
Halozyme Therapeutics addressed its Q1 earnings call with focus on the top five analyst questions covering financial results, product pipeline progress, and future guidance. Q1 earnings call analysis offers moderate insight into performance metrics and outlook but rarely shifts long-term company trajectory.

15 May

4 StockStory, 4:20 PM
Halozyme Therapeutics expands royalties via partnerships and advances pipeline candidates, positioning the company for stronger revenue and growth outlook through 2026 after Q1 results. Royalty expansion and pipeline progress represent major strategic drivers likely to alter revenue trajectory and investor positioning into 2026.

12 May

4 Insider Monkey, 5:28 PM
Halozyme Therapeutics (HALO) announces global collaboration and license agreement with GSK to develop and commercialize subcutaneous formulations of GSK's oncology and specialty medicines using HALO's ENHANZE drug delivery technology. Global partnership with GSK leverages HALO's ENHANZE platform for multiple products, unlocking milestone payments, royalties, and expanded market reach.

4 MT Newswires, 11:54 AM
Halozyme Therapeutics (HALO) beat Q1 earnings expectations due to royalty revenue outperformance and strong demand, as highlighted by Morgan Stanley. Q1 earnings beat from core royalty strength and demand signals significant positive momentum for financial performance and stock sentiment.

4 GuruFocus.com, 3:06 AM
Halozyme Therapeutics Inc. (HALO) posted record revenue growth in Q1 2026 earnings call, driven by key milestones in ENHANZE platform partnerships and royalty revenues exceeding expectations. Record revenue growth from ENHANZE partnerships signals major positive shift in financial trajectory and investor confidence.

11 May

4 www.marketbeat.com, 8:09 PM
Halozyme Therapeutics shared Q1 earnings call highlights, covering financial results, pipeline updates, and forward guidance. Q1 earnings highlights detail financial performance and strategic updates that could significantly sway investor sentiment and stock trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us